33 results about "Polyyne" patented technology

The invention provides methods for cyclizing poly-yne compounds under mild conditions to provide cyclic compounds.

The invention relates to a method for the preparation of a coating comprising at least one coating layer on a substrate, the method comprising the steps of a. providing monomers of the type R—(N)x-(L)m-(C═C)n-(L′)o-(N′)y—R′, wherein R is a head moiety, R′ is a tail moiety, (C≡C)n is an oligoyne moiety, L and L′ are linker moieties, N and N′ independently are branched or unbranched optionally substituted C1-C25 alkyl moieties optionally containing 1 to 5 heteroatoms, x, m, o, and y are independently 0 or 1, n is 4 to 12, and wherein the head moiety allows for an interaction with the surface of the substrate; b. bringing the monomers into contact with the substrate wherein the interaction of the head moieties of the monomers with the surface of the substrate induces at least a part of the monomers to align in a defined manner thereby forming a film on the surface and bringing the oligoyne moieties of the monomers into close contact with each other; c. inducing a reaction between oligoyne moieties by providing an external stimulus so as to at least partially cross-link the aligned monomers, thereby forming a coating layer on the substrate. The invention further relates to a coating obtainable according to the method of the invention, the use of a coating obtainable according to the method of the invention, a substrate comprising a coating obtainable according to the invention and the use of solid substrate. The invention further relates to a method for the synthesis of the monomers according to the invention.

The invention belongs to the field of medicines, and in particular relates to the use of polyacetylenic compounds for reducing uric acid. The polyalkyne compound has a structure shown in formula (I): R 1 and R 2 As shown in the definition of the description of the present invention. The present invention finds through the animal model of hyperuricemia that the polyalkyne compound of the present invention has significant uric acid-lowering effect in vivo, and can be used as a potential uric acid-lowering or gout-treating drug.

The present application relates to emitters exhibiting aggregation-induced luminescence, wherein T1, T2 and T3 comprise one or more polyynes as conjugate bridges. The present application also relates to an AIEgen comprising: a hydrophilic pyridyl group as a strong electron-withdrawing group; a piperazine group and an α-cyano-stilbene as an electron-donating group; wherein the AIEgen exhibits aggregation induced luminescence. The present application also relates to a method for synthesizing AIEgen, and further relates to a labeling method, the method comprising: incubating an object having cells with a conjugate formed by conjugating AIEgen with an antibody; and selecting by light-up imaging Target cells are selectively stained by AIEgen's fluorescence emission based on antibody degradation following cellular internalization of the conjugate through endocytosis.

The invention belongs to the field of pharmacy, and relates to the use of spiroketal polyacetylene compounds in the preparation of sensitization drugs for drug-resistant Staphylococcus aureus. Oxacillin can produce antibacterial and synergistic effects in a synergistic manner, especially through the combination of spiroketal polyacetylenes and oxacillin, it can significantly reduce the minimum inhibitory concentration of oxacillin, and has a negative effect on oxacillin. Synergistic effect against drug-resistant Staphylococcus aureus. The spiroketal polyacetylene compound can be used in the sensitization drug against the multi-drug resistant Staphylococcus aureus strain EMRSA‑16 containing the mecA efflux pump drug resistance gene, and the compound and oxacillin A pharmaceutical composition with anti-drug-resistant Staphylococcus aureus effect.

The invention relates to the fields of organic chemistry and metal organic chemistry, and discloses a chain polyacetylene compound, a preparation method of the compound, and an application of the compound to prepare a metal fused heterocyclic compound. The provided chain polyacetylene compound has the structure shown in the formula I. The invention further discloses a preparation method of the chain polyacetylene compound and an application of the chain polyacetylene compound to synthesize the metal fused heterocyclic compound. The chain polyacetylene compound contains multiple functional groups, is controllable in structure, and can be directly used to synthesize the metal fused heterocyclic compound with high efficiency. The chain polyacetylene compound is simple in synthetic method and can be fast effectively obtained.

The invention belongs to the field of medicines, and in particular relates to the use of a polyalkyne compound for treating gout. The polyalkyne compound has a structure shown in formula (I): R 1 , R 2 , R 3 and R 4 As shown in the definition of the description of the present invention. The present invention finds through the animal model of hyperuricemia that the polyalkyne compound of the present invention has significant uric acid-lowering effect in vivo, and can be used as a potential uric acid-lowering or gout-treating drug.

The present invention belongs to the field of chemical medicine, and specifically relates to a pharmaceutical composition for hyperuricemia and its use, including polyalkyne compounds having the structure shown in formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof , solvates, polymorphs, hydrates or derivatives in combination with hyperuricemia drugs in the preparation of a combined drug for the treatment of hyperuricemia, also provides a hyperuricemia pharmaceutical composition, comprising the above compound, and one of benzbromarone or lesinard. The drug composition for hyperuricemia can have a uric acid-lowering effect equivalent to or even better than that of the hyperuricemia drug in the prior art, but can significantly reduce the toxic and side effects of the drug for hyperuricemia, improve safety, and can be used It is used for the treatment of hyperuricemia and gout or gout complications caused by hyperuricemia.

The invention is an infrared microwave compatible stealth composite material based on helical polyyne and its preparation method. The composite material is composed of a propargyl amine monomer containing chiral cholic acid substituents in a core-shell conductive polymer / double metal nickel base The surface of oxide nanomaterials is in-situ polymerized into a composite of helical polyyne. The core-shell conductive polymer / double metal nickel-based oxide nanomaterial is composed of amine conductive polymer monomers on the surface of double metal nickel-based oxides. Self-polymerized, bimetallic nickel-based oxides are prepared from the third main group metal salt and nickel nitrate by hydrothermal reaction and high-temperature roasting, and the helix formed by in-situ polymerization of propargylamine monomers containing chiral cholic acid substituents The general structural formula of the polyyne is: the degree of polymerization n is 500-3000; the thermal decomposition temperature of the polyyne is 200°C-450°C, and the absolute value of the specific optical rotation at room temperature is 5°-70°.

A composition for use in prevention, inhibition and / or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in preventing and / or treating coccidiosis, and / or enhancing growth in an animal is disclosed, the composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.

The invention discloses a method for preparing electrostatic spraying polyacetylene particles and belongs to the field of electrostatic spinning. According to the method, an electrostatic spraying technology is utilized, a helix substituted acetylene polymer polyphenylene (PPA) and helix substituted propyne polymers (PFA (perfluoroalkoxy), PSA (polysulfonamide), PCFM, PX (para xylene)) are adoptedas representatives, and polyacetylene particles with uniform particle size distribution can be prepared by controlling the concentration of a polymer electrostatic spraying solution and adjusting related electrostatic spraying parameters. In order to further enrich the types and preparation methods of the polyacetylene particles, a copolymer of two monomers (FA / PA) copolymer and a comixture of polymers (PFA / PPA) of the monomers are further adopted for electrostatic spraying, by adjusting a copolymer composition ratio and a comixture composition ratio, structures, morphologies and chiral properties of particles can be adjusted, and multiple types of morphology adjustable polymer particles can be prepared. The method is simple to operate, uniform in particle size distribution, good in dispersibility and good in applicability.

The present disclosure is directed to a traceless directing group in a radical cascade. The chemo- and regioselectivity of the initial attack in skipped oligoalkynes is controlled by a propargyl alkoxy moiety. Radical translocations lead to the boomerang return of radical center to the site of initial attack where it assists to the elimination of the directing functionality via β-scission in the last step of the cascade. In some aspects, the reaction of the present invention is catalyzed by a stannane moiety, which allows further via facile reactions with electrophiles as well as Stille and Suzuki cross-coupling reactions. This selective radical transformation opens a new approach for the controlled transformation of skipped oligoalkynes into polycyclic ribbons of tunable dimensions.